In Silico Evaluation of Pharmacokinetic Properties and Drug Likeness of Statins Targeting Histone deacetylase
Current Research in Health Sciences · 26.06.2026 · 4 (1) · 24
DOI: 10.58613/crhs415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Research in Health Sciences, online erschienen am 26.06.2026. Verfasst von Mohammed Zuheir Hassan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Drug repurposing holds great potential in terms of discovering new anticancer agents via assigning new therapeutic uses to already approved drugs. Through epigenetic regulation of gene expression, histone deacetylase 3 (HDAC3) functions with great importance in the progression of breast cancer making it an attractive molecular target. We report a full in silico profiling of selected statins (Atorvastatin, Fluvastatin, Pitavastatin, Pravastatin, and Rosuvastatin) as potential HDAC inhibitors compared to the Histone deacetylase 3 crystal structure (PDB ID: 4LXZ) and reference inhibitor Vorinostat. Molecular docking results reveal that all of the evaluated statins dock in the HDAC catalytic pocket and interact with the catalytic Zn2 + ion. Atorvastatin showed the best binding affinity (-10.93 Kcal.mol– 1) followed by Vorinostat (-8.51 Kcal.mol– 1) and stable metal coordination most likely hydrogen bonding and series of π–π interactions with the active-site residues. Structure–activity relationship analyses revealed that both hydrophobic surface area, aromatic moieties and accessibility of the carboxylate zinc-binding group have a major effect on binding stability. Full ADMET profile showed good pharmacokinetic characteristics for most statins, with high predicted absorption from the gut, moderate distribution, amenable metabolic profiles, and generally acceptable toxicity predictions, although atorvastatin showed possible AMES positivity and hERG II inhibition. These computational studies indicate that statins appear to act as very weak non-classical HDAC inhibitors, especially Atorvastatin, consistent with the concept of repurposing these drugs as possible epigenetic anticancer agents.
Zitieren
APA
Hassan, M. Z., Abduljawad, A. R., Alshams, J. K., Shaheed, D. Q., & Radhi, A. J. (2026). In Silico Evaluation of Pharmacokinetic Properties and Drug Likeness of Statins Targeting Histone deacetylase. Current Research in Health Sciences, 4(1), 24. https://doi.org/10.58613/crhs415
Vancouver
Hassan MZ, Abduljawad AR, Alshams JK, Shaheed DQ, Radhi AJ. In Silico Evaluation of Pharmacokinetic Properties and Drug Likeness of Statins Targeting Histone deacetylase. Current Research in Health Sciences. 2026;4(1):24. doi:10.58613/crhs415
BibTeX
@article{Hassan2026,
author = {Hassan, Mohammed Zuheir and Abduljawad, Ahmed Ridha and Alshams, Jawad Kadhim and Shaheed, Dhurgham Qasim and Radhi, Ali Jabbar},
title = {In Silico Evaluation of Pharmacokinetic Properties and Drug Likeness of Statins Targeting Histone deacetylase},
journal = {Current Research in Health Sciences},
year = {2026},
volume = {4},
number = {1},
pages = {24},
doi = {10.58613/crhs415}
}
EUVIMED